Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

BACKGROUND: There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be inappropriate, as the study designs and patient populations could differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cartron, Guillaume, Fox, Christopher P., Liu, Fei Fei, Kostic, Ana, Hasskarl, Jens, Li, Daniel, Bonner, Ashley, Zhang, Yixie, Maloney, David G., Kuruvilla, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953336/
https://www.ncbi.nlm.nih.gov/pubmed/35337365
http://dx.doi.org/10.1186/s40164-022-00268-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953336/
https://www.ncbi.nlm.nih.gov/pubmed/35337365
http://dx.doi.org/10.1186/s40164-022-00268-z

Ejemplares similares